Cardiovascular profile in osteoarthritis: a meta-analysis of cardiovascular events and risk factors

Mathieu, Sylvain; Couderc, Marion; Tournadre, Anne; Soubrier, Martin

doi:10.1016/j.jbspin.2019.06.013

Cited by 51 publications

(46 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, 24 participants (29%) purchased either an indoor or outdoor bike (47% already owned a bike) and 25 participants (30%) joined a gym (12% were already a member). In addition to the important musculoskeletal benefits of exercise, these results are encouraging given the higher cardiovascular risk in patients with osteoarthritis due to inactivity [28], and the multiple benefits of exercise on all long-term chronic conditions usually faced by this age range of patients [29].…”

Section: Discussionmentioning

confidence: 94%

Self-Management of Hip Osteoarthritis Five Years After a Cycling and Education Treatment Pathway

et al. 2020

View full text Add to dashboard Cite

The Cycling against Hip Pain (CHAIN) programme is a six-week cycling and education treatment pathway for people with hip osteoarthritis. Preliminary results demonstrated significant improvements in clinical and patient-reported outcome measures following the course. Whilst the benefits of exercise for osteoarthritis are often reported in the short term, less is known about the long-term effects for this patient group. This study explores whether participants continued to self-manage their hip osteoarthritis five years after completing the course. A cross-sectional survey was conducted to collect data from participants who completed the CHAIN programme between October 2013 and February 2015 (n = 96). Questionnaires were sent by post in April 2019, and then non-responders were followed up again four weeks later. Eighty-three (87%) participants responded to the survey. Five years (range 4–6) after completion of a six-week cycling and education programme, 37 (45%) participants had not returned to their general practitioner for further treatment of their hip pain, and 47 (57%) had not pursued surgical intervention. All participants were still engaged in at least one physical activity per week and many reported that they had purchased a bike (29%), joined a gym (30%) or cycled regularly (indoor cycling 25%, outdoor cycling 24%). Eighty (96%) participants reported an increase in knowledge of self-managing their symptoms. The findings from this study suggest that many patients are motivated to self-manage their hip osteoarthritis, five years following a six-week cycling and education treatment pathway that encourages lifestyle change.

show abstract

Section: Discussionmentioning

confidence: 94%

Self-Management of Hip Osteoarthritis Five Years After a Cycling and Education Treatment Pathway

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Comorbidities have been reported to be more frequent in patients with OA compared with other diseases and to lead to greater deterioration of physical functions and QoL. OA increases cardiovascular mortality [24], worsens the prognosis of arthroplasties, and reduces the range of possibilities of pharmacological treatment due to the incompatibility of prescribed drugs to alleviate joint pain and treat comorbidities [4]. Finally, our results revealed a high prevalence of gastrointestinal problems which may be a consequence of the high use of NSAIDs, the oral OA treatment of choice in the majority of the cases and is related to gastrointestinal adverse effects [25].…”

Section: Discussionmentioning

confidence: 99%

“…However, many of these drugs cannot be used for a long time due to their adverse effects and incompatibility with medications used for OA-associated comorbidities. [24,[40][41][42][43] Furthermore, it has been previously reported that OA patients are concerned about possible side effects of medication. [44] This evidence, in association with our results, highlights the need for investment in research for new and more active OA pharmacological treatments.…”

Section: Discussionmentioning

confidence: 99%

A patients’ view of OA: the Global Osteoarthritis Patient Perception Survey (GOAPPS)

Vitaloni¹,

Bemden

Sciortino

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Globally, osteoarthritis (OA) is the third condition associated with disability. There is still poor treatment in OA but science holds the key to finding better treatments and a cure. It is essential to learn what’s important to patients from them to implement the most effective OA management. The OA Patients Task Force, conducted the Global OA Patient Perception Survey (GOAPPS)-the first global survey to compare the quality of life (QoL) & patient perceptions of care across countries. The goal was to collect data on OA patients' perception of OA to understand patients’ needs and expectations to improve OA management.Methods: Observational, cross-sectional study by online survey data collection from six countries, translated into three languages. The survey was comprised of 3 sections: patient demographics and clinical symptomology characteristics; relationship with physicians: perception of attention, treatment, and information provided; and OA impact on daily activity and QoL. The results of the survey were evaluated using the Limited Data Set. The survey results were analyzed using descriptive statistics to characterize the patients' answers using the IBM SPSS® software.Results. A total of 1512 surveys were completed in 6 countries. 84.2% of respondents reported pain/tenderness and 91.1% experienced limitations to physical activities. 42.3% of patients were not satisfied with their current OA treatment. 86% had comorbidities, especially hypertension, and obesity. 51.3% and 78% would like access to additional drug or additional non-drug/non-surgical treatments respectively. 48.2% of patients perceived their QoL to be affected by OA Conclusions: OA has a significant impact on patients’ daily activities and their desire to play an active role in managing this disease. Patients are seeking additional treatments, especially no pharmacological/no surgical treatments stressing the need for investing in clinical research, implementing OA preventive measures, and managing interventions to improve the healthcare value chain in OA.

show abstract

“…Sarcopenia and obesity were frequently reported, affecting 22% to 30% of the patients with OA [35,36]. An increased risk of myocardial infarction, stroke and metabolic syndrome was also reported as well as atherogenic lipid profile, elevated fasting glucose [37]. Metabolic syndrome, CV disease and OA are then closely related.…”

Section: Cardiometabolic Comorbidities In Other Rheumatic Diseasesmentioning

confidence: 99%

Could Omega 3 Fatty Acids Preserve Muscle Health in Rheumatoid Arthritis?

2020

Self Cite

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by a high prevalence of death due to cardiometabolic diseases. As observed during the aging process, several comorbidities, such as cardiovascular disorders (CVD), insulin resistance, metabolic syndrome and sarcopenia, are frequently associated to RA. These abnormalities could be closely linked to alterations in lipid metabolism. Indeed, RA patients exhibit a lipid paradox, defined by reduced levels of total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol whereas the CVD risk is increased. Moreover, the accumulation of toxic lipid mediators (i.e., lipotoxicity) in skeletal muscles can induce mitochondrial dysfunctions and insulin resistance, which are both crucial determinants of CVD and sarcopenia. The prevention or reversion of these biological perturbations in RA patients could contribute to the maintenance of muscle health and thus be protective against the increased risk for cardiometabolic diseases, dysmobility and mortality. Yet, several studies have shown that omega 3 fatty acids (FA) could prevent the development of RA, improve muscle metabolism and limit muscle atrophy in obese and insulin-resistant subjects. Thereby, dietary supplementation with omega 3 FA should be a promising strategy to counteract muscle lipotoxicity and for the prevention of comorbidities in RA patients.

show abstract

Cardiovascular profile in osteoarthritis: a meta-analysis of cardiovascular events and risk factors

Cited by 51 publications

References 34 publications

Self-Management of Hip Osteoarthritis Five Years After a Cycling and Education Treatment Pathway

Self-Management of Hip Osteoarthritis Five Years After a Cycling and Education Treatment Pathway

A patients’ view of OA: the Global Osteoarthritis Patient Perception Survey (GOAPPS)

Could Omega 3 Fatty Acids Preserve Muscle Health in Rheumatoid Arthritis?

Contact Info

Product

Resources

About